Bioinova

Name

Bioinova

Legal name

Bioinova, a.s.

Website

https://bioinova.cz

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Praha

HQ country

Czechia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Revenue model

1. Stem Cell-Based Medicinal Products: Bioinova manufactures its own investigational medicinal products (BiCure® orthoMSCp, BiCure® ophthalmoMSCs) from autologous stem cells. Products are tested in Phase I–II clinical trials. As investigational products, revenue is not yet commercialized but represents the primary product pipeline.
2. GMP Consulting Services: Provides consultancy services in GMP activities including aseptic manufacturing implementation, production process validation, quality management system establishment, GMP process auditing, gap analysis, corrective action planning, and preparation for external audits and certifications.
3. Tissue Establishment & Tissue Banking: Operates certified tissue establishment and tissue bank (www.detskyzoubek.cz) for collection, processing, testing, release, storage, and distribution of human tissues including bone marrow and dental pulp. Provides services to tissue establishments and dental practices.
4. Contract Development & Manufacturing of ATMPs: Contract development and manufacturing of advanced therapy medicinal products (ATMPs) for clinical trials under GMP conditions, including validation batch manufacturing and IMPD (Investigational Medicinal Product Dossier) preparation.
5. GMP Quality Control Services: Provides sterility testing (pharmacopoeial methods and Bact/ALERT), cleanroom monitoring (particle and microbiological), cell phenotyping by flow cytometry, and mycoplasma detection by quantitative PCR to external clients.
6. In Vitro Diagnostic Products: Manufactures and distributes IVD products including Bi-CoV® (viral RNA sampling kit), Bi-Micro® (bacterial/viral DNA/RNA sampling kit), Bi-VirTest® (rapid viral infection test), and Bi-Reader® (quantitative test reader) primarily through distributor channels.
7. Specialized Cell Storage Solutions: Manufactures and sells specialized GMP-grade formulations BiCureSol® and BiCureChill® for storage, transport, and cryopreservation of stem cells to pharmaceutical companies and research institutions.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

No source content was provided for analysis; core offerings cannot be determined.

Product overview

Bioinova offers a diversified portfolio of biotech products organized into four main categories: (1) Medicinal Products including BiCure® ortho MSCp for knee cartilage repair and BiCure® ophthalmo MSCs for degenerative retinal diseases; (2) In Vitro Diagnostics including Bi-CoV® and Bi-Micro® sampling kits for PCR-ready sample collection, Bi-VirTest® rapid immunochromatographic test for viral detection, and Bi-Reader® hardware for quantitative test evaluation; (3) Specialized Solutions including BiCureSol® for short-term cell transport (72+ hours at 2-8°C) and BiCureChill® for cryopreservation and long-term storage; (4) Services encompassing Tissue Bank operations, GMP consulting, GMP quality control, ATMP contract manufacturing, and GCP clinical trial services. The product portfolio spans regenerative medicine, molecular diagnostics, and pharmaceutical support solutions.

Differentiator

Problem solved

Functional benefit

Brands

• BiCure® ortho MSCp: Stem cell-based medicinal product for treatment of damaged articular cartilage using cultured autologous mesenchymal stem cells on 3D scaffold
• BiCure® ophthalmo MSCs
• BiCureSol®
• BiCureChill®
• Bi-CoV®
• Bi-Micro®
• Bi-VirTest®
• Bi-Reader®

Quantifiable outcome

• BiCureSol® preserves stem cell viability at 92.2% and immunophenotype at 99.0% after 72 hours at 2–8 °C
• +4 more outcomes

Named customers6 records

Segments5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature8 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Ústav experimentální medicíny AV ČR, v.v.i. (Institute of Experimental Medicine of the Czech Academy of Sciences)coreStrategic or Co-development PartnerBioinova was founded in 2008 as a spin-off of the Institute of Experimental Medicine of the Czech Academy of Sciences. The institute and Bioinova co-develop ATMPs including the stem cell medicinal product from umbilical cord Wharton jelly (OP PIK project, CZ.01.1.02/0.0/0.0/20_321/0025145). The institute serves as the primary applicant with Bioinova as partner.
• University of Oslo (Prof. Dr. med. Dr. rer. nat. Jens Pahnke E.F.N.)coreStrategic or Co-development PartnerAcademic co-development partner in TAČR KAPPA 2 project (TO01000078, 2021–2024) focused on advanced development of compounds for Alzheimer's disease treatment. Funded by Norwegian Funds and Technology Agency of the Czech Republic. Max support 35,212,148 CZK with 85% from Norwegian funds and 15% from TA ČR.
• GEMINI Eye Clinic a.s., Zlín (Retinal Center)coreStrategic or Co-development PartnerClinical trial site for BiCure® ophthalmoMSCs Phase I clinical trial (EU Trial Number: 2023-503573-38-00) for treatment of degenerative retinal diseases. Ophthalmologists from the clinic collaborate with Bioinova on clinical evaluation of the stem cell therapy.
• Fakultní nemocnice Hradec Králové (University Hospital Hradec Králové)coreStrategic or Co-development PartnerLead partner in TAČR KAPPA 2 project (TO01000078) with doc. PharmDr. Ondřej Soukup Ph.D. as principal investigator. Also Phase II clinical trial site for BiCure® orthoMSCp (EU Trial Number: 2023-503486-32-00) for knee cartilage damage treatment.
• Masaryk Hospital, Ústí nad Labem (Department of Orthopedics and Sports Medicine)coreStrategic or Co-development PartnerPhase I clinical trial site for BiCure® orthoMSCp (EudraCT Number: 2018-004067-31). Completed clinical trial with 6 patients over 2-year follow-up. Results published in Neckář et al., 2023.
• IVD Distributors (seeking new partners)minorChannel Partner/ Reseller/ DistributorBioinova is actively seeking new distribution partners to bring its in vitro diagnostic products (Bi-CoV®, Bi-Micro®, Bi-VirTest®, Bi-Reader®) to the Czech and international markets. Offers full service, expert consulting, and support to distribution partners.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Market position

Competitive moat4 records

Key highlights7 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioinova